NSE: DIVISLAB · 23 October 2026
- Divi's Laboratories Limited shares fell 3.12% on October 23, 2026, closing at ₹8,876.50 after trading between an intraday high of ₹9,167.50 and a low of ₹8,797.50.
- The company successfully convened its 36th Annual General Meeting through video conferencing, where shareholders adopted the audited financial statements for the financial year ended March 31, 2026. The meeting also approved a final dividend of ₹30 per equity share of face value ₹2 each (1,500%) and cleared the re-appointment of directors retiring by rotation, including Mr. N.V. Ramana and Dr. Kiran S. Divi.
- Trading volume was 1.01 times the 20-day average daily volume.
Why is Divi S Laboratories share price falling on 23 October 2026?
Divi's Laboratories Limited shares fell 3.12% on October 23, 2026, closing at ₹8,876.50 after trading between an intraday high of ₹9,167.50 and a low of ₹8,797.50.
The broader market and sector felt negative pressure during the trading day, with the Nifty falling 0.90% and the Nifty Pharma sector benchmark declining 1.08%. Divi's Laboratories lagged slightly behind the sector drop while extending a softer 20-day return trend of -7.77%, reflecting broader caution across pharmaceutical equities.
Company filings indicate that while upcoming financial results for the quarter ending September 30, 2026, are scheduled for board approval on November 7, 2026, no single same-day corporate catalyst was announced to explain today's down move. The downward price action aligns with broader sector weakness and technical profit-taking following recent market conditions.
5.68 lakh shares traded by 23 October 2026 · 03:00 PM IST. This compares with a 20-day average daily volume of 5.62 lakh shares (1.01 times). The five-day average daily volume was 7.20 lakh shares. Separately, the NSE report for 22 October 2026 showed 7.92 lakh shares delivered, representing 76.11% of that day’s traded volume. The same report recorded 61,741 trades.
The stock decline lacks a specific same-day news catalyst. The downward price action matches broader weakness across the Nifty Pharma index alongside normal volume participation.
Latest Company Developments
The company successfully convened its 36th Annual General Meeting through video conferencing, where shareholders adopted the audited financial statements for the financial year ended March 31, 2026. The meeting also approved a final dividend of ₹30 per equity share of face value ₹2 each (1,500%) and cleared the re-appointment of directors retiring by rotation, including Mr. N.V. Ramana and Dr. Kiran S. Divi.
Confirms the formal adoption of annual accounts and the approval of shareholder-return distributions for the preceding fiscal year.
Divi's Laboratories announced the retirement of Mr. L. Ramesh Babu, Vice President (Procurement), and Mr. D. Madhu Babu, Vice President (Projects), effective from the close of business hours on July 31, 2026. Both personnel ceased to be Senior Management Personnel of the company due to superannuation.
Reflects standard leadership transitions in key operational verticals of procurement and project execution.
Divi's Laboratories Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.
Divi's Laboratories Limited has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.
'Information regarding deduction of Income tax at source from payment of Dividend for the financial year 2025-26'.
Ownership & Transaction Activity
Mutual Fund Holdings
Mutual funds held 14.66% on 30 September 2026. This compares with 13.87% on 30 June 2026, a change of +0.79 percentage points.
The filing reported 49 MF/UTI holders.
What to Watch Next
- Board meeting and financial results announcement scheduled for November 7, 2026, covering the quarter and half-year ended September 30, 2026.
- Trading volume trends relative to the 20-day average volume benchmark during subsequent trading sessions.
- Price behavior near key support levels following the intraday low of ₹8,797.50.
- Broader performance of the Nifty Pharma sector index and currency movements affecting export-oriented drugmakers.
Other Dated Coverage
- Divi S Laboratories Share Price Today: Why DIVISLAB Is Rising 0.40% | 7 October 2026 — 7 October 2026
- Why Divi's Laboratories Shares Are Rising 3.85% Today | 6 October 2026 — 6 October 2026
- Why Divi's Lab Shares Fell 3.27% Today: Market Context & Analysis | 1 October 2026 — 1 October 2026
More Divi S Laboratories news and dated analysis →
Frequently Asked Questions
What is the latest Divi S Laboratories company news?
The company successfully convened its 36th Annual General Meeting through video conferencing, where shareholders adopted the audited financial statements for the financial year ended March 31, 2026. The meeting also approved a final dividend of ₹30 per equity share of face value ₹2 each (1,500%) and cleared the re-appointment of directors retiring by rotation, including Mr. N.V. Ramana and Dr. Kiran S. Divi.
How strong was Divi S Laboratories’s trading volume?
5.68 lakh shares traded, 1.01 times the 20-day average daily volume. The price and volume data are dated 23 October 2026 · 03:00 PM IST.
Do the mutual-fund figures show buying today?
They show holdings on 30 September 2026. Quarterly holdings do not identify purchases made on the article date.
Research & analysis: WittyTrades Research Desk
Reviewed by: Mohanish Sanghavi — SEBI Registered Research Analyst
Disclaimer: Investments in securities markets are subject to market risks. Registration with SEBI and NISM certification do not guarantee performance or returns. This article is for information and education, not personalised investment advice or a recommendation to buy, sell or hold.